Dataset Information

A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.

ABSTRACT: The estimated hepatitis C virus (HCV) carriers are approximately 10 million in Pakistan which usually progresses to chronic hepatitis, with rare cases of spontaneous viral eradication. The present article reviews the treatment status of HCV infection in Pakistani population and various factors associated with the treatment response rates.Literature on anti-HCV therapy was searched in PubMed, Google Scholar and PakMediNet. Thirty three different studies representing different geographic regions of Pakistan published from 2002 to 2016 were included in the present review. Weighted mean, standard error estimates (SE) and standard deviation (SD) were determined for each population group.Mean value for sustained virological response (SVR) for standard IFN plus ribavirin (RBV) combination therapy was 68.38%?±?14.13% (range 33.8%-87.10%; SE 3.08) and pegylated-IFN plus RBV combination therapy 64.38%?±?8.68% (range 55.0%-76.00%; SE 3.88). The lowest value for SVR has been reported to be 24.3% (for genotype 1; administering INF-? 2b 3MU 3 times/week and RBV 1000-1200?mg/day for 48 weeks) while highest of 87.5% (genotype 3a; INF-? 2a 3MU 3 times/week and RBV 1000-1200?mg/day for 24 weeks). The mean value for rapid virological response (RVR) was found to be 48.18%?±?29.20% (SE 9.73). As PEG-interferon and direct acting antivirals (DAAs) are relatively expensive, interferon-alfa (IFN-?) and RBV combination therapy have been used widely to treat HCV infected patients in Pakistan for the last one and half decade. On average, 2.45% of the patients discontinued treatment due to severe side effects.We encourage further studies on understanding host and viral factors associated with specific focus on harder to treat viral variants (relapsers and nonresponders). These variants are currently rising in the country.

SUBMITTER: Ali M

PROVIDER: S-EPMC5268021 | biostudies-other | 2016 Dec

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.

Ali Muhammad M Afzal Samia S Zia Asad A Hassan Ahmed A Khalil Ali Talha AT Ovais Muhammad M Shinwari Zabta Khan ZK Idrees Muhammad M

Medicine 20161201 50

<h4>Background</h4>The estimated hepatitis C virus (HCV) carriers are approximately 10 million in Pakistan which usually progresses to chronic hepatitis, with rare cases of spontaneous viral eradication. The present article reviews the treatment status of HCV infection in Pakistani population and various factors associated with the treatment response rates.<h4>Methods</h4>Literature on anti-HCV therapy was searched in PubMed, Google Scholar and PakMediNet. Thirty three different studies represen ...[more]

PMID: 27977575

Similar Datasets

Project description:IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, exhibiting a variable clinical and pathological course and significantly contributing to the global burden of chronic kidney disease and end-stage renal disease. Current standards of care focus on optimization of antihypertensive and antiproteinuric therapies (typically renin- angiotensin system blockade) to reduce disease progression. Much recent attention has focused on whether additional immunosuppression confers better outcomes than supportive management alone, and indeed, several trials have demonstrated renoprotective effects following the use of oral corticosteroids. However, results have been inconsistent, and perceived benefits must be balanced against risks and adverse effects associated with generalized immunosuppression, as highlighted by the high-profile STOP-IgAN and TESTING clinical trials. Recent translational research in vitro and animal models of IgAN have generated greater insight into potential therapeutic targets for this complex autoimmune disease. Deeper understanding of the roles of the mucosal immune barrier, complement activation and deposition, T-cell dependent and independent mechanisms of B cell activation, and of the deposition and downstream inflammatory signaling pathways of nephritogenic polymeric IgA1 complexes (e.g., signaling of immune receptors via spleen tyrosine kinase) has formed the rationale for the development of novel agents and clinical trials of more targeted therapies. However, translating findings into clinical practice is challenging, with many immunopathological features of IgAN specific to humans. Recent comprehensive reviews outline current understanding of mechanisms of IgAN as well as ongoing and future clinical trials; it is not our aim to replicate this here. Instead, we take a mechanistic approach to current treatment strategies, outlining advantages and limitations of each before exploring ongoing research with potential translation into future targeted therapies for this complex disease.

Dataset Information

A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.

Publications

A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets